(VIANEWS) – The Market ended the session with GENTIAN DIAGNOSTIC (GENT.OL) rising 9.41% to kr46.50 on Friday, after five consecutive sessions in a row of losses. Oslo Børs Benchmark Index_GI jumped 0.83% to kr1,242.70, following the last session’s upward trend on what was a somewhat up trend exchanging session today.
GENTIAN DIAGNOSTIC’s last close was kr42.50, 14.83% below its 52-week high of kr49.90.
About GENTIAN DIAGNOSTIC
Gentian Diagnostics ASA researches, develops, and produces biochemical reagents for use in medical diagnostics and research in Europe, Asia, and the United States. It offers in-vitro diagnostic reagents for clinical chemistry analyzers. The company's products include the gentian calprotectin immunoassay, a turbidimetric immunoassay used for the measurement of calprotectin in plasma and serum for detection and assessment of inflammation; Cystatin C, a superior GFR marker for the diagnosis and therapeutic control of renal function; NT-proBNP Immunoassay for diagnosis, monitoring, and assessment of severity in individuals suspected of having congestive heart failure; and Canine c-reactive protein (CRP) immunoassay, a particle-enhanced turbidimetric immunoassay for quantitative determination of canine CRP in dog plasma and serum. It also provides turbidimetric SARS-CoV-2 total antibody immunoassay, a quantitative antibody test for detecting antibodies targeting the S1-subunit. Gentian Diagnostics ASA was incorporated in 2001 and is headquartered in Moss, Norway.
Earnings Per Share
As for profitability, GENTIAN DIAGNOSTIC has a trailing twelve months EPS of kr-1.16.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -10.94%.
Revenue Growth
Year-on-year quarterly revenue growth grew by 45.5%, now sitting on 122.43M for the twelve trailing months.
Volatility
GENTIAN DIAGNOSTIC’s last week, last month’s, and last quarter’s current intraday variation average was a negative 5.17%, a negative 0.36%, and a positive 2.00%.
GENTIAN DIAGNOSTIC’s highest amplitude of average volatility was 5.17% (last week), 2.52% (last month), and 2.00% (last quarter).
Stock Price Classification
According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, GENTIAN DIAGNOSTIC’s stock is considered to be overbought (>=80).
Yearly Top and Bottom Value
GENTIAN DIAGNOSTIC’s stock is valued at kr46.50 at 22:30 EST, below its 52-week high of kr49.90 and way higher than its 52-week low of kr35.00.
More news about GENTIAN DIAGNOSTIC (GENT.OL).
